Xencor, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XNCR research report →
About the company
Xencor Inc. , a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders.
- CEO
- Bassil I. Dahiyat
- IPO
- 2013
- Employees
- 250
- HQ
- Pasadena, CA, US
Price Chart
- Market Cap
- $1.11B
- P/E
- -6.55
- P/S
- 11.42
- P/B
- 2.19
- EV/EBITDA
- -9.67
- Div Yield
- 0.00%
- Gross Margin
- 36.15%
- Op Margin
- -217.93%
- Net Margin
- -177.10%
- ROE
- -28.77%
- ROIC
- -30.58%
- Revenue
- $125.58M · 13.65%
- Net Income
- $-91,923,000 · 60.48%
- EPS
- $-1.24 · 65.36%
- Op Income
- $-177,502,000
- FCF YoY
- 33.62%
- 52W High
- $18.69
- 52W Low
- $6.92
- 50D MA
- $12.59
- 200D MA
- $13.16
- Beta
- 0.93
- Avg Volume
- 822.00K
Get TickerSpark's AI analysis on XNCR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 18, 26 | Feigal Ellen | sell | 6,843 |
| Jun 15, 26 | GORMAN KEVIN CHARLES | sell | 7,527 |
| Jun 15, 26 | GUSTAFSON KURT A | sell | 5,474 |
| Jun 15, 26 | RANIERI RICHARD J | sell | 5,474 |
| Jun 15, 26 | Montgomery Alan Bruce | sell | 5,064 |
| Apr 10, 26 | Cornelissen Bart Jan | sell | 3,499 |
| Mar 5, 26 | Desjarlais John R | sell | 4,118 |
| Mar 6, 26 | Desjarlais John R | sell | 2,502 |
| Mar 5, 26 | Eckert Celia | sell | 3,244 |
| Mar 6, 26 | Eckert Celia | sell | 1,767 |
Our XNCR coverage
Recent articles, reports, and earnings notes.
Vesicor Therapeutics Is Going Public via SPAC — Here’s the Setup
Vesicor Therapeutics, a preclinical oncology gene-therapy company, is going public via merger with Black Hawk Acquisition Corp (BKHA). The deal is still pending in the latest June 2026 filing, and the setup hinges on whether redemptions and dilution leave enough capital for a real biotech runway.
Veraxa Biotech AG IPO: What Investors Need to Know
Veraxa Biotech AG Ordinary Shares (NASDAQ: VRXA) is expected to list on 2026-06-10, but the price range has not been disclosed. This is a SPAC business combination rather than a traditional IPO, with the story centered on a pre-commercial oncology pipeline. Bull case: a differentiated antibody-therapy platform; bear case: no product revenue yet and heavy financing needs.
Want a deeper read on XNCR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.